Our previous studies utilized rat models to demonstrate that CSP may treat NAFLD through the p38 mitogen-activated protein kinase (MAPK) and JUN N-terminal kinase (JNK) pathways [10–12]. The gene discussed is MAPK8; the disease is metabolic dysfunction-associated steatotic liver disease.